Friday’s Midday Movers: Clovis Oncology (CLVS), TG Therapeutics (TGTX), Blueprint Medicines (BPMC), Arrowhead Research (ARWR), United States Steel (X)

By Carrie Williams

So far Friday, November 29, NASDAQ is up 0.26% and the S&P is down -0.36%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Clovis Oncology (CLVSResearch Report), TG Therapeutics (TGTXResearch Report), Blueprint Medicines (BPMCResearch Report), Arrowhead Research (ARWRResearch Report) and United States Steel (XResearch Report).

Clovis Oncology is up 10.62% in midday trading to $14.37. Shares opened today at $12.99. The company has a 52-week low of $2.93 and a 52-week high of $32.05. On the Street’s front, the average 12-month analyst price target for the stock is $11.42, marking a -12.09% potential downside from current levels. In a report issued on November 19, Evercore ISI analyst Joshua Schimmer downgraded CLVS to Hold, with a price target of $8.00, which implies a downside of 38% from current levels. Separately, on November 8, H.C. Wainwright’s Edward White reiterated a Buy rating on the stock and has a price target of $36.00.

TG Therapeutics is up 6.31% in midday trading to $8.26. Shares opened today at $7.77. The company has a 52-week low of $3.32 and a 52-week high of $9.38. On the Street’s front, the average 12-month analyst price target for the stock is $16.00, marking a 105.92% potential upside from current levels. In a report issued on November 27, B.Riley FBR analyst Mayank Mamtani initiated coverage with a Buy rating on TGTX and a price target of $12.00, which represents a potential upside of 54% from where the stock is currently trading.

Blueprint Medicines is up 5.83% in midday trading to $81.89. Shares opened today at $77.38. The company has a 52-week low of $44.58 and a 52-week high of $102.98. On the Street’s front, the average 12-month analyst price target for the stock is $103.86, marking a 34.22% potential upside from current levels. In a report issued on November 7, H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on BPMC, with a price target of $100.00, which implies an upside of 29% from current levels. Separately, on October 28, Deutsche Bank’s Konstantinos Aprilakis downgraded the stock to Hold and has a price target of $75.00. In the last 30 days, insiders purchased $37.4K worth of BPMC shares. Over the last 3 months, the insider sentiment on Blueprint Medicines has been positive based on 31 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Arrowhead Research is up 5.41% in midday trading to $73.00. Shares opened today at $69.25. The company has a 52-week low of $10.41 and a 52-week high of $73.72. On the Street’s front, the average 12-month analyst price target for the stock is $67.60, marking a -2.38% potential downside from current levels. In a report released today, Chardan analyst Keay Nakae reiterated a Buy rating on ARWR, with a price target of $81.00, which represents a potential upside of 17% from where the stock is currently trading. Separately, on November 19, Cantor Fitzgerald’s Elemer Piros maintained a Hold rating on the stock and has a price target of $50.00. In the last 30 days, insiders purchased $65.65K worth of ARWR shares. Over the last 3 months, the insider sentiment on Arrowhead Research has been negative based on 43 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

United States Steel is down -5.35% in midday trading to $13.01. Shares opened today at $13.74. The company has a 52-week low of $9.93 and a 52-week high of $24.74. On the Street’s front, the average 12-month analyst price target for the stock is $11.38, marking a -17.18% potential downside from current levels. In a report issued on November 26, Credit Suisse analyst Curt Woodworth maintained a Sell rating on X. Separately, on November 5, Argus’ David Coleman downgraded the stock to Hold . In the last 30 days, insiders purchased $22.56K worth of X shares. Over the last 3 months, the insider sentiment on United States Steel has been positive based on 57 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Trending Stocks Based on Insider Activity >>